Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
PYPD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $3.93
Previous CloseN/A
Volume10.68K
Average Volume (3M)105.59K
Market Cap
$34.85M
Enterprise Value$32.47M
Total Cash (Recent Filing)$5.61M
Total Debt (Recent Filing)$11.78M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 05, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding10,190,904
10 Day Avg. Volume79,053
30 Day Avg. Volume105,592
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$12.33Price Target Upside260.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCompelling data from the SHIELD II Phase 3 trial of D-PLEX100 in Surgical Site Infections supports the approval and commercial potential of D-PLEX100.
Financial StabilityThe company has strengthened its cash position through additional financing, extending operations into the third quarter of 2025.
Regulatory ApprovalD-PLEX100 has received Fast Track and Breakthrough designations, which supports a faster regulatory review process.
Bears Say
Market PerceptionThe market appears to assign a lower probability of success to D-PLEX100 than it is believed it deserves.
Trial Size IncreaseThe DSMB's recommendation to increase the trial size to 800 subjects suggests a meaningful signal of benefit for D-PLEX100.
PolyPid News
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $2.30 and its highest was $3.93 in the past 12 months.
What is PolyPid Ltd.’s market cap?
PolyPid Ltd.’s market cap is $34.85M.
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is Nov 05, 2025 which is in 83 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on Aug 13, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.232.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -0.52.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 10,190,904 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went up 2.047%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Currently, no hedge funds are holding shares in PYPD
PolyPid Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (260.53% Upside)
$12.33 (260.53% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.56%
12-Months-Change
Fundamentals
Return on Equity
-853.05%
Trailing 12-Months
Asset Growth
-33.65%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing, manufacturing, and commercializing novel, locally administered therapies to improve surgical outcomes. The company operates predominantly in the healthcare sector, specializing in products that provide controlled and extended release of medications at surgical sites. PolyPid's core product candidate, D-PLEX100, is designed to deliver antibiotics directly to targeted areas to prevent surgical infections.
PYPD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress and positive indicators for D-PLEX100, with successful trial enrollment and strong market potential. However, financial challenges such as increased net loss and R&D expenses present notable concerns.View all PYPD earnings summariesPYPD Stock 12 Month Forecast
Average Price Target
$12.33
▲(260.53% Upside)
Technical Analysis
Pluri
―
Collplant Holdings
―
Grace Therapeutics
―
VYNE Therapeutics
―
Aligos Therapeutics
―
Ownership Overview
21.60%
Insiders
19.87% Other Institutional Investors
58.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---